MedLife launches the EarlyCDT® test, which allows early detection of lung cancer by identifying specific autoantibodies, available in all its units.

MedLife Group, the leading private healthcare provider in Romania, has introduced the EarlyCDT® test, a blood-based immunologic test for the early detection of lung cancer. It identifies autoantibodies produced by the body up to 4 years before visible lesions appear. The test is non-invasive and is mainly targeted at people with risk factors, with a turnaround time of about 15 days. Studies show that the use of this test reduces late-stage diagnoses by 36%, increasing the chances of survival. MedLife reaffirms its commitment to innovation in laboratory medicine.